Payal Kohli

2.7k total citations · 1 hit paper
43 papers, 2.0k citations indexed

About

Payal Kohli is a scholar working on Surgery, Cardiology and Cardiovascular Medicine and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Payal Kohli has authored 43 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Surgery, 15 papers in Cardiology and Cardiovascular Medicine and 11 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Payal Kohli's work include Lipoproteins and Cardiovascular Health (23 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (10 papers) and Antiplatelet Therapy and Cardiovascular Diseases (7 papers). Payal Kohli is often cited by papers focused on Lipoproteins and Cardiovascular Health (23 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (10 papers) and Antiplatelet Therapy and Cardiovascular Diseases (7 papers). Payal Kohli collaborates with scholars based in United States, France and Canada. Payal Kohli's co-authors include Bruce D. Levy, Marc S. Sabatine, Scott M. Wasserman, Robert C. Scott, Laura E. Fredenburgh, Caroline Bonnans, Koichi Fukunaga, Robert P. Giugliano, Elaine Hoffman and Nihar R. Desai and has published in prestigious journals such as The Lancet, JAMA and Circulation.

In The Last Decade

Payal Kohli

43 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study

2012 354 citations Payal Kohli, Satishkumar Mohanavelu et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Payal Kohli United States	19	890	400	375	371	280	43	2.0k
Michael S. Kostapanos Greece	25	1.1k 1.2×	140 0.3×	509 1.4×	491 1.3×	161 0.6×	79	2.5k
Lοukianos S. Rallidis Greece	29	931 1.0×	178 0.4×	324 0.9×	1.5k 3.9×	109 0.4×	172	3.3k
Núria Plana Spain	29	1.4k 1.6×	189 0.5×	197 0.5×	689 1.9×	288 1.0×	161	2.9k
Marcelo Chiara Bertolami Brazil	25	685 0.8×	146 0.4×	133 0.4×	345 0.9×	113 0.4×	71	1.9k
Michal Vráblík Czechia	26	946 1.1×	121 0.3×	106 0.3×	387 1.0×	163 0.6×	167	2.0k
Benjamin J. Ansell United States	22	1.9k 2.2×	515 1.3×	182 0.5×	711 1.9×	185 0.7×	33	3.9k
A Notarbartoló Italy	34	2.2k 2.5×	274 0.7×	242 0.6×	999 2.7×	183 0.7×	152	4.3k
Craig Granowitz United States	18	1.6k 1.8×	195 0.5×	992 2.6×	1.0k 2.8×	243 0.9×	55	3.2k
Jean Bergeron Canada	29	1.3k 1.5×	146 0.4×	199 0.5×	620 1.7×	205 0.7×	80	2.9k
Tanja B. Grammer Germany	36	936 1.1×	257 0.6×	449 1.2×	906 2.4×	100 0.4×	110	3.7k

Countries citing papers authored by Payal Kohli

Since Specialization

Citations

This map shows the geographic impact of Payal Kohli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Payal Kohli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Payal Kohli more than expected).

Fields of papers citing papers by Payal Kohli

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Payal Kohli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Payal Kohli. The network helps show where Payal Kohli may publish in the future.

Co-authorship network of co-authors of Payal Kohli

This figure shows the co-authorship network connecting the top 25 collaborators of Payal Kohli. A scholar is included among the top collaborators of Payal Kohli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Payal Kohli. Payal Kohli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Blumenthal, Roger S., et al.. (2025). High-sensitivity C-reactive Protein in Atherosclerotic Cardiovascular Disease: To Measure or Not to Measure?. US Cardiology Review. 19. e06–e06. 4 indexed citations

Mhaimeed, Omar, et al.. (2024). The importance of LDL-C lowering in atherosclerotic cardiovascular disease prevention: Lower for longer is better. SHILAP Revista de lepidopterología. 18. 100649–100649. 39 indexed citations

Blumenthal, Roger S., et al.. (2024). The ABCs of the 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease. Clinical Cardiology. 47(5). e24284–e24284. 2 indexed citations

Gami, Abhishek, et al.. (2023). Applying the ABCs of Cardiovascular Disease Prevention to the 2023 AHA/ACC Multisociety Chronic Coronary Disease Guidelines. The American Journal of Medicine. 137(2). 85–91. 3 indexed citations

Drahos, Jennifer, Payal Kohli, Sarah Acaster, et al.. (2023). PCR132 Symptoms and Impacts of Transfusion-Dependent Beta-Thalassemia: A Qualitative Interview Study and the Development of a Conceptual Model. Value in Health. 26(6). S336–S336. 1 indexed citations

Kohli, Payal, et al.. (2022). COVID’s Impact on Non-communicable Diseases: What We Do Not Know May Hurt Us. Current Cardiology Reports. 24(7). 829–837. 9 indexed citations

Ho, K. S., et al.. (2020). Halting Sepsis with Aspirin?. A6012–A6012. 1 indexed citations

Kohli, Payal, Peiqi Wang, Andrew Wang, et al.. (2020). PREDICTORS OF FFR UNDERUTILIZATION. Journal of the American College of Cardiology. 75(11). 106–106. 2 indexed citations

Agarwala, Anandita, Payal Kohli, & Salim S. Virani. (2019). Popular Media and Cardiovascular Medicine: “with Great Power There Must Also Come Great Responsibility”. Current Atherosclerosis Reports. 21(11). 43–43. 7 indexed citations

10.

Abbasi, Fahim, Payal Kohli, Gerald M. Reaven, & Joshua W. Knowles. (2016). Hypertriglyceridemia: A simple approach to identify insulin resistance and enhanced cardio-metabolic risk in patients with prediabetes. Diabetes Research and Clinical Practice. 120. 156–161. 18 indexed citations

11.

Kohli, Payal, Peter Ganz, Yifei Ma, et al.. (2016). HIV and Hepatitis C–Coinfected Patients Have Lower Low‐Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent “PCSK9–Lipid Paradox”. Journal of the American Heart Association. 5(5). 35 indexed citations

12.

Arsenault, Benoît J., Payal Kohli, Gilles Lambert, et al.. (2016). Emerging Cardiovascular Disease Biomarkers and Incident Diabetes Mellitus Risk in Statin-Treated Patients With Coronary Artery Disease (from the Treating to New Targets [TNT] Study). The American Journal of Cardiology. 118(4). 494–498. 5 indexed citations

13.

Kohli, Payal, David D. Waters, Rita Nemr, et al.. (2015). Risk of New-Onset Diabetes and Cardiovascular Risk Reduction From High-Dose Statin Therapy in Pre-Diabetics and Non–Pre-Diabetics. Journal of the American College of Cardiology. 65(4). 402–404. 35 indexed citations

14.

Kohli, Payal, Philippe Gabríel Steg, Sidney C. Smith, et al.. (2013). NSAID Use and Association with Cardiovascular Outcomes in Outpatients with Stable Atherothrombotic Disease. The American Journal of Medicine. 127(1). 53–60.e1. 45 indexed citations

15.

Kohli, Payal, et al.. (2012). プロタンパク質転換酵素サブチリシンKexin9型(PCSK9)に対する完全ヒトモノクローナル抗体AMG145は,ハイリスク患者におけるNCEP低密度リポタンパク質-コレステロール目標値の達成を促進する. Circulation. 126(23). 2791. 1 indexed citations

16.

Gopalakrishnan, Lakshmi, et al.. (2012). Pharmacokinetic evaluation of rivaroxaban for the treatment of acute coronary syndromes. Expert Opinion on Drug Metabolism & Toxicology. 8(7). 889–900. 4 indexed citations

17.

Kohli, Payal & Christopher P. Cannon. (2011). Walking the tightrope between efficacy and bleeding. Nature Reviews Cardiology. 9(2). 69–71. 4 indexed citations

18.

Kohli, Payal & Bruce D. Levy. (2009). Resolvins and protectins: mediating solutions to inflammation. British Journal of Pharmacology. 158(4). 960–971. 229 indexed citations

19.

Levy, Bruce D., Payal Kohli, Katherine Gotlinger, et al.. (2007). Protectin D1 Is Generated in Asthma and Dampens Airway Inflammation and Hyperresponsiveness. The Journal of Immunology. 178(1). 496–502. 277 indexed citations

20.

Fukunaga, Koichi, Payal Kohli, Caroline Bonnans, Laura E. Fredenburgh, & Bruce D. Levy. (2005). Cyclooxygenase 2 Plays a Pivotal Role in the Resolution of Acute Lung Injury. The Journal of Immunology. 174(8). 5033–5039. 234 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact